Literature DB >> 12355446

An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection.

James Alexander1, Frank Brombacher, H Adrienne McGachy, Andrew N J McKenzie, William Walker, K Christine Carter.   

Abstract

A comparison of the growth of Leishmania mexicana in IL-4(-/-), IL-4Ralpha(-/-) and wild-type BALB/c mice demonstrated a disease exacerbative role for IL-13 as well as IL-4. Thus, while both IL-4(-/-) and IL-4Ralpha(-/-) mice were more resistant than wild-type controls to infection with L. mexicana, IL-4Ralpha(-/-) mice, which are unresponsive to IL-13 as well as IL-4, were significantly more resistant to parasite growth than their IL-4(-/-) counterparts. Cytokine and antibody analysis revealed a Th1-biased specific response in both infected IL-4(-/-) and IL-4Ralpha(-/-) mice compared with wild-type animals. Reconstituting SCID mice with IL-4(-/-), IL-4Ralpha(-/-) or wild-type splenocytes prior to infection demonstrated that the early onset of lesion growth was dependent on the presence of lymphocytes responding to IL-4 and/or IL-13, as lesions failed to develop in only the SCID IL-4Ralpha(-/-) reconstituted mice. An independent role for IL-13 in L. mexicana infection was demonstrated by comparing disease progression in IL-13(-/-), IL-4(-/-)/IL-13(-/-) and wild-type B6/129 mice. In contrast to IL-4(-/-)/IL-13(-/-) mice, which were resistant, IL-13(-/-) mice developed lesions similar in size to wild-type animals up to week 8 post-infection. However, in contrast to wild-type mice in which disease continued to progress, lesions eventually healed in IL-13(-/-) mice, in association with the development of a Th1 response. Collectively our results suggest that IL-4 plays a critical role in early lesion development, and that IL-13 plays a crucial part in maintaining a chronic non-healing infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355446     DOI: 10.1002/1521-4141(2002010)32:10<2923::AID-IMMU2923>3.0.CO;2-E

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

1.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

2.  Infection with arginase-deficient Leishmania major reveals a parasite number-dependent and cytokine-independent regulation of host cellular arginase activity and disease pathogenesis.

Authors:  Helen M Muleme; Rosa M Reguera; Alicia Berard; Richard Azinwi; Ping Jia; Ifeoma B Okwor; Stephen Beverley; Jude E Uzonna
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

3.  Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions.

Authors:  Laurence U Buxbaum; Phillip Scott
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

4.  Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease.

Authors:  Tiago M Castilho; Karen Goldsmith-Pestana; Caterin Lozano; Liliana Valderrama; Nancy G Saravia; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

5.  Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Authors:  Anne Maurer-Cecchini; Saskia Decuypere; François Chappuis; Coralie Alexandrenne; Simonne De Doncker; Marleen Boelaert; Jean-Claude Dujardin; Louis Loutan; Jean-Michel Dayer; Gianfranco Tulliano; Jorge Arevalo; Alexandro Llanos-Cuentas; Carlo Chizzolini
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

Review 6.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

7.  Expression of multiple CPB genes encoding cysteine proteases is required for Leishmania mexicana virulence in vivo.

Authors:  Hubert Denise; Kathryn McNeil; Darren R Brooks; James Alexander; Graham H Coombs; Jeremy C Mottram
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

8.  Overexpression of the natural inhibitor of cysteine peptidases in Leishmania mexicana leads to reduced virulence and a Th1 response.

Authors:  Karen Bryson; Sébastien Besteiro; H Adrienne McGachy; Graham H Coombs; Jeremy C Mottram; James Alexander
Journal:  Infect Immun       Date:  2009-05-11       Impact factor: 3.441

9.  Visceral Leishmania donovani infection in interleukin-13-/- mice.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 10.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.